TSFAE20c:Demographic Characteristics for Subjects With Treatment-emergent Adverse Events - [FDA Medical Query of Interest / Preferred Term of Interest]; Safety Analysis Set (Study jjcs - core)
Active Study Agent
Xanomeline High Dose
Xanomeline Low Dose
Combined
Placebo
Characteristic
N=53
N=73
N=126
N=59
Subjects with ≥ 1 Abdominal Pain
46 (86.8%)
54 (74.0%)
100 (79.4%)
33 (55.9%)
Sex, n/Ns (%)
Male
28/29 (96.6%)
27/34 (79.4%)
55/63 (87.3%)
14/23 (60.9%)
Female
18/24 (75.0%)
27/39 (69.2%)
45/63 (71.4%)
19/36 (52.8%)
Age group (years), n/Ns (%)
≥18 to <65
7/8 (87.5%)
3/5 (60.0%)
10/13 (76.9%)
3/7 (42.9%)
≥65 to <75
12/16 (75.0%)
14/17 (82.4%)
26/33 (78.8%)
10/19 (52.6%)
≥75
27/29 (93.1%)
37/51 (72.5%)
64/80 (80.0%)
20/33 (60.6%)
Race, n/Ns (%)
American Indian or Alaska Native
5/5 (100.0%)
9/10 (90.0%)
14/15 (93.3%)
2/3 (66.7%)
Asian
9/10 (90.0%)
6/9 (66.7%)
15/19 (78.9%)
3/5 (60.0%)
Black or African American
3/3 (100.0%)
7/11 (63.6%)
10/14 (71.4%)
4/7 (57.1%)
Native Hawaiian or other Pacific Islander
6/7 (85.7%)
5/5 (100.0%)
11/12 (91.7%)
4/5 (80.0%)
White
7/8 (87.5%)
6/8 (75.0%)
13/16 (81.2%)
4/7 (57.1%)
Multiple
8/8 (100.0%)
7/10 (70.0%)
15/18 (83.3%)
1/5 (20.0%)
Not reported or unknown
7/11 (63.6%)
9/12 (75.0%)
16/23 (69.6%)
11/17 (64.7%)
Other
1/1 (100.0%)
5/8 (62.5%)
6/9 (66.7%)
4/10 (40.0%)
Ethnicity, n/Ns (%)
Hispanic or Latino
12/15 (80.0%)
12/15 (80.0%)
24/30 (80.0%)
6/12 (50.0%)
Not Hispanic or Latino
13/15 (86.7%)
12/18 (66.7%)
25/33 (75.8%)
10/16 (62.5%)
Not reported or unknown
21/23 (91.3%)
30/40 (75.0%)
51/63 (81.0%)
17/31 (54.8%)
Note: n=number of subjects with at least one event, Ns=total number of subjects for each specific subgroup